Crossmark

Synergistic Interactions Between the Quinolone-Derived Compound HT61 and Tobramycin Against a Range of Clinical Isolates of Pseudomonas aeruginosa In Vitro

Crossref DOI link: https://doi.org/10.1007/s00408-025-00855-x

Published Online: 2025-11-27

Published Print: 2025-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ramsden, B. https://orcid.org/0009-0003-8951-4349
Kelis, A. V. https://orcid.org/0009-0001-9160-367X
Faure, M.-E. https://orcid.org/0000-0001-7554-0317
Page, C. P. https://orcid.org/0000-0002-9358-3799
Amison, R. T. https://orcid.org/0000-0002-6616-4599
License Information

Text and Data Mining valid from 2025-11-27

Version of Record valid from 2025-11-27
More Information

Article History

Received: 28 July 2025

Accepted: 20 October 2025

First Online: 27 November 2025

Declarations

:

: CP declares that he holds equity in Helperby Therapeutics who are developing HT61. There are no other conflicts of interest to declare.

Document is current

Any future updates will be listed below